Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ShigETEC vaccine in healthy adults
NCT05409196Phase 1Completed
- Sponsor
- Eveliqure Biotechnologies
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ShigETEC in shigellosis and enterotoxigenic Escherichia coli infection (9 arms), sponsored by Eveliqure Biotechnologies. Primary endpoints: Number and percentage of participants with treatment related acute adverse events post vaccination, Number and percentage of participants with any adverse event up to 110 days and 3 more. Started Sep 2020; status: completed.
02
Drugs
ShigETEC
03
Conditions
shigellosisenterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT05409196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409196.